Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine receptor agonist presented as a 2‑8 mg/24 h transdermal patch for transdermal use. The patch delivers continuous dopaminergic stimulation over a 24‑hour period, helping to manage motor fluctuations in Parkinson's disease and to reduce uncomfortable sensations in Restless Legs Syndrome in adult patients.

GNH USA supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and timely delivery to meet patient needs.

Rotigotine is a dopamine agonist used in the management of movement disorders. - Parkinson's disease: Improves overall motor function and reduces rigidity, tremor, and bradykinesia in adults with idiopathic Parkinson's disease. - Motor fluctuations in Parkinson's disease: Provides continuous dopaminergic stimulation to lessen OFF episodes and improve wearing‑off phenomena. - Restless Legs Syndrome: Decreases the frequency and severity of uncomfortable leg sensations and urges to move in adults with moderate to severe RLS.

Rotigotine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Skin irritation at the patch site: Redness, itching or rash where the patch is applied. - Nausea: Mild to moderate feeling of stomach upset. - Dizziness: Light‑headedness, especially when standing quickly. - Somnolence: Increased sleepiness or fatigue during the day. - Headache: Tension‑type or mild throbbing pain. - Dry mouth: Reduced salivation causing thirst. - Constipation: Decreased bowel movements.

Serious or Rare Side Effects: - Hallucinations: Visual or auditory disturbances that may affect perception. - Impulse control disorders: Compulsive gambling, shopping or eating behaviors. - Orthostatic hypotension: Significant drop in blood pressure upon standing, leading to faintness. - Severe skin reactions: Bullous dermatitis or severe erythema requiring medical attention. - Neuroleptic malignant syndrome: Rare but life‑threatening condition with fever, muscle rigidity and autonomic instability.

When prescribing rotigotine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: Evaluate for orthostatic hypotension or arrhythmias before initiating therapy. - Psychiatric history: Monitor patients with a history of psychosis or impulse control disorders. - Renal function: Adjust use cautiously in severe renal impairment. - Hepatic impairment: Use with caution in moderate to severe liver disease. - Pregnancy and lactation: Avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at room temperature: Keep patches below 25 °C in the original pouch, protected from moisture and direct sunlight.

Rotigotine can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - MAO‑B inhibitors: Concomitant use may cause hypertensive crises or severe hypotension. - Antipsychotics with strong dopamine antagonism: May reduce rotigotine’s efficacy and worsen motor symptoms.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): Can increase rotigotine plasma levels. - CYP3A4 inducers (e.g., carbamazepine): May reduce rotigotine exposure. - Antihypertensive agents: Combined effect may exacerbate orthostatic hypotension. - Other dopamine agonists: Additive risk of impulse control disorders.